Also I think you have to consider the time factor for big pharma.
AD214 has taken a decade to get to this point. Let's say 3 years have been wasted along the way for various reasons, but that's still 7 years from discovery to end of Phase 1.
With patents running out and an ever increasing need to keep the revenue streams ticking along, for an upfront payment of $45m big pharma can save themselves not only the cost of developing the drug ($45m to date), but also the 7 years of development, not to mention mitigation of the risk involved, as there is no guarantee that even after 7 years they could get a drug ready to start phase 2, with a safety profile and novel mode of action in a multi billion dollar market.
Therefore with that in mind I don't think the best light to view the upfront is against current MC, I believe it's against the time and risk mitigation for big pharma in getting an alternative drug to this stage of development, therefore in that light, a $45m upfront and another $45m for phase II trials, so under $100m gets you a drug that in three years could be starting a Phase III in a multi billion dollar indication with little or no competition
- Forums
- ASX - By Stock
- 1AD
- Ann: Positive AD-214 Phase I extension study results
Ann: Positive AD-214 Phase I extension study results, page-169
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
-0.002(7.41%) |
Mkt cap ! $13.33M |
Open | High | Low | Value | Volume |
2.7¢ | 2.7¢ | 2.5¢ | $8.326K | 319.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 217861 | 2.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 196034 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 217861 | 0.025 |
2 | 664357 | 0.024 |
2 | 320000 | 0.023 |
4 | 355000 | 0.022 |
3 | 1197615 | 0.021 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 196034 | 2 |
0.027 | 469977 | 2 |
0.029 | 92629 | 3 |
0.030 | 810875 | 4 |
0.032 | 230000 | 1 |
Last trade - 15.47pm 28/05/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online